Treatment of HIV-associated nephropathy.
HIV-associated nephropathy (HIVAN) is the most common cause of renal failure in patients infected with type 1 human immunodeficiency virus (HIV-1). The renal prognosis for HIVAN is poor and is typically associated with rapid progression to renal death. We report a patient with biopsy-proven HIVAN who was successfully treated with corticosteroids and review the currently available evidence supporting the specific treatments of this condition. A 34-year-old African-American male with a 2-year history of uncomplicated HIV disease developed progressive azotemia despite treatment with highly active antiretroviral therapy (HAART). He was treated with an uncomplicated 4-month course of prednisone, which improved his serum creatinine from 2.9 to 1.9 mg/dl and decreased his degree of proteinuria from 8 to 2.1 g/day. Two years post-steroid treatment his renal function remains stable. Increasing evidence supports that both ACE inhibitors and HAART are effective in preventing and in some cases of reversing HIVAN induced renal failure. In selected patients who progress despite these measures, a limited course of corticosteroid may achieve long-standing disease remissions. In general, with adequate supervision, corticosteroid therapy appears to be well tolerated and has an acceptable side effect profile. Although persuasive in view of the abysmal natural history of HIVAN, the currently available studies are subject to major methodological limitations. Appropriate randomized controlled trials are urgently required in order to further examine the efficacy, optimal timing, and potential side effects of these treatments.
Sothinathan
R
R
Division of Nephrology, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Briggs
W A
WA
Eustace
J A
JA
D016263:AIDS-Associated Nephropathy / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D005938:Glucocorticoids / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D005938:Glucocorticoids; D011241:Prednisone